Presented by:
Ms. Elizabeth M.Sc (N)
Asst. Professor,
Dept of MSN
NNC, GNSU.
Alzheimer's disease
Alzheimer’s disease is an irreversible, progressive brain
disease that slowly destroys memory and disorders
cognitive function
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Although the risk of developing AD increases with age – in
most people with AD, symptoms first appear after age 60
(5% incidence) AD is not a part of normal aging.
Alzheimer's disease
Alzheimer's disease
Pathophysiology and Etiology
Gross pathophysiologic changes:
✓ cortical atrophy
✓ enlarged ventricles
✓ basal ganglia wasting
Microscopically:
– Changes in the proteins of the nerve cells of the
cerebral cortex
– accumulation of neurofibrillary tangles and
neuritic plaques (deposits of protein and altered
cell structures on the interneuronal junctions)
granulovascular degeneration
– loss of cholinergic nerve cells (important in
memory, function, cognition
• Biochemically: neurotransmitter systems are
impaired
• Cause: unknown
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Alzheimer's disease
Diagnosis
• Medical history, history from relatives, and
behavioural observations.
• Neurological Examination and MSE
• CT, MRI, SPECT, PET can be used to help
exclude other cerebral pathology
Lab diagnosis
• complete blood count, sedimentation rate,
chemistry panel, thyroid-stimulating
hormone, test for syphilis, urinalysis, serum
B12, folate level, and test for HIV
• to rule out infectious or metabolic disorders
• cerebrospinal fluid (CSF) - tau protein and
beta-amyloid
Genetic testing
In families with a history of Alzheimer's
disease, test to confirm AD or to provide
information to at-risk family members regarding
their likelihood for development of AD
How is Alzheimer’s Disease managed at present?
• Ideally, management should involve an interdisciplinary
approach for assessment, treatment & education
• The roles of nutritionists, caregivers, nurses, social workers
and patients associations can be vital for the long term care
• Pharmacological treatment
– Cholinesterase inhibitors
– Memantine
The 3 targets for Pharmacotherapy
• Cognitive decline: memory, language,
orientation, concentration, etc.
• Behavioral abnormalities: delusions,
aggressiveness, anxiety, depression, psychosis
etc..
• Activities of Daily Living: dressing, bathing,
feeding, use of household appliances, etc
CHOLINESTERASE INHIBITORS
• Rivastigmine
• Galantamine
• Donepezil
Nicotine is a cholinergic agonist that acts both
postsynaptically and pre-synaptically to release
acetylcholine
Melatonin - This neurohormone prevents
neuronal death caused by exposure to the
amyloid beta protein
Donepezil (Aricept)
• Widely used in mild to moderate cases
because it can be given once daily and is well
tolerated
• Starting at 5 mg hs and increased to 10 mg
after 4 to 6 weeks
Galantamine
• Given with food in dosage of 4 to 12 mg bid
Should be restarted at 4 mg bid if interrupted
for several days
• Dose should be reduced in cases of renal or
hepatic impairment
Rivastigmine
• Given 1.5 mg bid with meals and increased up
to 6 to 12 mg per day
Memantine
• NMDA-receptor antagonist
• The first of a new class approved for moderate
to severe Alzheimer's
• Dosage is 10 mg bid
• Can be used with a cholinesterase inhibitor
• Patients with depressive symptoms should be
considered for antidepressant therapy
• Behavioral disturbances may require
pharmacologic treatment anxiolytics,
antipsychotics, anticonvulsants
Nonpharmacologic treatments used to improve
cognition:
• Environmental manipulation that decreases
stimulation
• Aromatherapy, Massage, Music therapy,
Exercise
Drug Alert
• Cholinesterase inhibitors initially aimed at improving memory and
cognition seem to have an important impact on the behavioral
changes that occur in patients with cognitive impairment
• improves the apathy, disinhibition, pacing, and hallucinations
commonly noted in dementia
• Be alert for drug interactions with NSAIDs, succinylcholine-type
muscle relaxants, cholinergic and anticholinergic agents, drugs that
slow the heart, and other drugs
Nursing assessment
• Perform cognitive assessment
• Orientation, insight, abstract thinking, concentration,
memory, verbal ability
• Assess for changes in behavior and ability to perform adls
• Evaluate nutrition and hydration
• Check weight, skin turgor, meal habits
• Assess motor ability, strength, muscle tone, flexibility
Nursing diagnoses
• Self-care deficit
• Constipation
• Disabled family coping
• Disturbed thought
• Imbalanced nutrition: Less than body
requirements Impaired verbal communication
• Ineffective coping
• Interrupted family processes
• Risk for infection
• Risk for injury
Interventions
• Establish an effective communication system
with the patient and his family to help them
adjust to the patient's altered cognitive
abilities
• Provide emotional support to the patient and
his family
• Encourage them to talk about their concerns
• Listen carefully to them
• Use a soft tone and a slow, calm manner when
speaking to him Because the patient may
misperceive his environment
• Allow the patient sufficient time to answer
your questions his thought processes are slow,
impairing his ability to communicate verbally
Intervention
• Administer ordered medications to the patient
and note their effects
• If the patient has trouble swallowing, check with
a pharmacist to see if tablets can be crushed or
capsules can be opened and mixed with a semi-
soft food
• Protect the patient from injury
• Provide a safe, structured environment
• Provide rest periods between activities because
these patients tire easily
• Encourage the patient to exercise to help
maintain mobility
• Encourage patient independence allow ample
time for the patient to perform tasks
• Encourage sufficient fluid intake and adequate
nutrition Provide assistance with menu selection
allow the patient to feed himself as much as he
can
• Provide a well-balanced diet with adequate fiber
• Avoid stimulants, such as coffee, tea, cola, and
chocolate
• Give the patient semisolid foods if he has dysphagia
• Insert and care for a nasogastric tube or a gastrostomy
tube for feeding as ordered
• Because the patient may be disoriented or
neuromuscular functioning may be impaired, take the
patient to the bathroom at least every 2 hours
• Assist the patient with hygiene and dressing as
necessary
• Many patients with Alzheimer's disease are incapable
of performing these tasks
Complication
• Aspiration
• Pneumonia and other infections
• Falls
• Fractures
• Bedsores
• Malnutrition or dehydration
Prevention
It is not a preventable condition.
Lifestyle risk factors for Alzheimer's can be
modified.
Changes in diet, exercise and habits — steps to
reduce the risk of cardiovascular disease — may
also lower your risk of developing Alzheimer's
disease
Heart-healthy lifestyle choices that may reduce
the risk of Alzheimer's include the following:
• Exercise regularly
• Eat a diet of fresh produce, healthy oils and
foods low in saturated fat
• Follow treatment guidelines to manage high
blood pressure, diabetes and high cholesterol
• Quit smoking
Alzheimer's disease

More Related Content

PPTX
Alzheimer powerpoint
PPTX
Alzheimer's disease
PPTX
Alzeihmer disease
PPTX
Alzheimer disease
PPTX
Alzheimer’s disease: Management
PPTX
Alzheimer s disease_powerpoint_skinner_kassandra
PPTX
ppt on Alzheimer’s disease
PPTX
Alzheimer’s disease
Alzheimer powerpoint
Alzheimer's disease
Alzeihmer disease
Alzheimer disease
Alzheimer’s disease: Management
Alzheimer s disease_powerpoint_skinner_kassandra
ppt on Alzheimer’s disease
Alzheimer’s disease

What's hot (20)

PPT
Alzheimer's disease
PPTX
Alzheimer’s disease
PDF
Pathophysiology and management of alzheimer's disease
PPTX
Alzheimer's Disease and its pathophysiology
PPSX
Alzheimer's disease
PPTX
Pathophysiology of Alzheimer's disease
PPTX
Alzheimer’s disease ppt
PPT
Alzheimer disease
PPTX
Alzheimer's disease
PPT
Mania ppt new
PPTX
Dementia ppt msc nursing
PPTX
Depression
PPTX
Alzheimer’s disease full
PPTX
Dementia : Symptoms, Causes and Treatment
PPTX
Antipsychotic drugs
PPTX
PPTX
Parkinson's
PPT
Huntington's Disease .ppt
PPTX
Alzheimer's disease
PPTX
Movement disorder - HUNTINGTON'S DISEASE(Chorea)
Alzheimer's disease
Alzheimer’s disease
Pathophysiology and management of alzheimer's disease
Alzheimer's Disease and its pathophysiology
Alzheimer's disease
Pathophysiology of Alzheimer's disease
Alzheimer’s disease ppt
Alzheimer disease
Alzheimer's disease
Mania ppt new
Dementia ppt msc nursing
Depression
Alzheimer’s disease full
Dementia : Symptoms, Causes and Treatment
Antipsychotic drugs
Parkinson's
Huntington's Disease .ppt
Alzheimer's disease
Movement disorder - HUNTINGTON'S DISEASE(Chorea)
Ad

Similar to Alzheimer's disease (20)

PPTX
Alzhiemer
PPTX
neuro disorder-alziemers.pptx explanation
PDF
Alzimers disease
PPTX
ALZHEMERS HEALTH EQUITY final Copy-1.pptx
PPTX
ALZIMER'S DISEASE.pptx
PPT
Alzheimer disease
PPTX
Alzheimer’s disease 2
PPTX
Alzheimer's disease
PPTX
Alzheimer's disease
PPTX
Safe discharge of dementia patients
PPTX
A class slide of ALZHEIMER’S DISEASE.pptx
PPTX
Alzheimer's disease
PPTX
Alzhemiers disease BY dr.MUMTAZ ALI.pptx
PPTX
Alzheimer's disease
PPTX
Alzheimer's Disease [A Complete Picture]
PPTX
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
PPTX
Alzheimer's disease1 neurodegenerative .pptx
PPTX
Alzhmier's Disease.pptx
PPTX
Alzheimer
PPTX
alzhemier's disease in neurological.pptx
Alzhiemer
neuro disorder-alziemers.pptx explanation
Alzimers disease
ALZHEMERS HEALTH EQUITY final Copy-1.pptx
ALZIMER'S DISEASE.pptx
Alzheimer disease
Alzheimer’s disease 2
Alzheimer's disease
Alzheimer's disease
Safe discharge of dementia patients
A class slide of ALZHEIMER’S DISEASE.pptx
Alzheimer's disease
Alzhemiers disease BY dr.MUMTAZ ALI.pptx
Alzheimer's disease
Alzheimer's Disease [A Complete Picture]
Alzheimer's disease : Overview, Symptoms, Risk Factor, Causes, Treatment and ...
Alzheimer's disease1 neurodegenerative .pptx
Alzhmier's Disease.pptx
Alzheimer
alzhemier's disease in neurological.pptx
Ad

More from Ms.Elizabeth (20)

PPTX
14. Brain Tumour.pptx
PPTX
12. Uterine Cancer
PPTX
5. COLORECTAL CANCER
PPTX
4. Gastric Cancer
PPTX
2. laryngeal Cancer - easy explanation
PPTX
3. Lung Cancer -for nursing students
PDF
Cardiac arrest - for nursing students
PDF
Adenoiditis - easy explanation for nursing students
PDF
Lymphoma
PPTX
Presbycusis
PPTX
Mastoiditis
PPTX
Furunculosis
PDF
Sarcoma
PDF
Atherosclerosis
PDF
Hypotension
PDF
Liver cancer
PDF
Bladder cancer
PDF
Hormone therapy
PDF
Brain tumor
PDF
Renal cancer
14. Brain Tumour.pptx
12. Uterine Cancer
5. COLORECTAL CANCER
4. Gastric Cancer
2. laryngeal Cancer - easy explanation
3. Lung Cancer -for nursing students
Cardiac arrest - for nursing students
Adenoiditis - easy explanation for nursing students
Lymphoma
Presbycusis
Mastoiditis
Furunculosis
Sarcoma
Atherosclerosis
Hypotension
Liver cancer
Bladder cancer
Hormone therapy
Brain tumor
Renal cancer

Recently uploaded (20)

PPTX
case study of ischemic stroke for nursing
PDF
ENT MedMap you can study for the exam with this.pdf
PPTX
Foundations of Toxicology: Understanding Harmful Effects on Life and Environment
PPTX
Mortality rate in a teritiary care center of infia july stats sncu picu
PDF
Fundamentals Final Review Questions.docx.pdf
PPTX
OSTEOMYELITIS and OSTEORADIONECROSIS.pptx
PPTX
Skeletal System presentation for high school
PPTX
ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
PDF
Art Therapy Exercises and Worksheets.pdf
PDF
Medical_Biology_and_Genetics_Current_Studies_I.pdf
DOCX
PT10 continues to explose your mind right after reading
PPTX
OccupationalhealthPPT1Phealthinindustriesandsafety.pptx
PDF
health promotion and maintenance of elderly
PDF
demography and familyplanning-181222172149.pdf
PPTX
Nepal health service act.pptx by Sunil Sharma
PPTX
Signs of Autism in Toddlers: Pediatrician-Approved Early Indicators
PPTX
osteoporosis in menopause...............
PPTX
1-back pain presentation presentation .pptx
PDF
Exploring The Impact of Bite-to-Needle Time on Snakebite Complications: Insig...
PPT
DENGUE_FEVER_&_DHF.pptfffffffffhffffffffffff
case study of ischemic stroke for nursing
ENT MedMap you can study for the exam with this.pdf
Foundations of Toxicology: Understanding Harmful Effects on Life and Environment
Mortality rate in a teritiary care center of infia july stats sncu picu
Fundamentals Final Review Questions.docx.pdf
OSTEOMYELITIS and OSTEORADIONECROSIS.pptx
Skeletal System presentation for high school
ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION
Art Therapy Exercises and Worksheets.pdf
Medical_Biology_and_Genetics_Current_Studies_I.pdf
PT10 continues to explose your mind right after reading
OccupationalhealthPPT1Phealthinindustriesandsafety.pptx
health promotion and maintenance of elderly
demography and familyplanning-181222172149.pdf
Nepal health service act.pptx by Sunil Sharma
Signs of Autism in Toddlers: Pediatrician-Approved Early Indicators
osteoporosis in menopause...............
1-back pain presentation presentation .pptx
Exploring The Impact of Bite-to-Needle Time on Snakebite Complications: Insig...
DENGUE_FEVER_&_DHF.pptfffffffffhffffffffffff

Alzheimer's disease

  • 1. Presented by: Ms. Elizabeth M.Sc (N) Asst. Professor, Dept of MSN NNC, GNSU.
  • 3. Alzheimer’s disease is an irreversible, progressive brain disease that slowly destroys memory and disorders cognitive function
  • 7. Although the risk of developing AD increases with age – in most people with AD, symptoms first appear after age 60 (5% incidence) AD is not a part of normal aging.
  • 10. Pathophysiology and Etiology Gross pathophysiologic changes: ✓ cortical atrophy ✓ enlarged ventricles ✓ basal ganglia wasting
  • 11. Microscopically: – Changes in the proteins of the nerve cells of the cerebral cortex – accumulation of neurofibrillary tangles and neuritic plaques (deposits of protein and altered cell structures on the interneuronal junctions) granulovascular degeneration – loss of cholinergic nerve cells (important in memory, function, cognition
  • 12. • Biochemically: neurotransmitter systems are impaired • Cause: unknown
  • 21. Diagnosis • Medical history, history from relatives, and behavioural observations. • Neurological Examination and MSE • CT, MRI, SPECT, PET can be used to help exclude other cerebral pathology
  • 22. Lab diagnosis • complete blood count, sedimentation rate, chemistry panel, thyroid-stimulating hormone, test for syphilis, urinalysis, serum B12, folate level, and test for HIV • to rule out infectious or metabolic disorders
  • 23. • cerebrospinal fluid (CSF) - tau protein and beta-amyloid Genetic testing In families with a history of Alzheimer's disease, test to confirm AD or to provide information to at-risk family members regarding their likelihood for development of AD
  • 24. How is Alzheimer’s Disease managed at present? • Ideally, management should involve an interdisciplinary approach for assessment, treatment & education • The roles of nutritionists, caregivers, nurses, social workers and patients associations can be vital for the long term care • Pharmacological treatment – Cholinesterase inhibitors – Memantine
  • 25. The 3 targets for Pharmacotherapy • Cognitive decline: memory, language, orientation, concentration, etc. • Behavioral abnormalities: delusions, aggressiveness, anxiety, depression, psychosis etc.. • Activities of Daily Living: dressing, bathing, feeding, use of household appliances, etc
  • 27. Nicotine is a cholinergic agonist that acts both postsynaptically and pre-synaptically to release acetylcholine Melatonin - This neurohormone prevents neuronal death caused by exposure to the amyloid beta protein
  • 28. Donepezil (Aricept) • Widely used in mild to moderate cases because it can be given once daily and is well tolerated • Starting at 5 mg hs and increased to 10 mg after 4 to 6 weeks
  • 29. Galantamine • Given with food in dosage of 4 to 12 mg bid Should be restarted at 4 mg bid if interrupted for several days • Dose should be reduced in cases of renal or hepatic impairment
  • 30. Rivastigmine • Given 1.5 mg bid with meals and increased up to 6 to 12 mg per day
  • 31. Memantine • NMDA-receptor antagonist • The first of a new class approved for moderate to severe Alzheimer's • Dosage is 10 mg bid • Can be used with a cholinesterase inhibitor
  • 32. • Patients with depressive symptoms should be considered for antidepressant therapy • Behavioral disturbances may require pharmacologic treatment anxiolytics, antipsychotics, anticonvulsants
  • 33. Nonpharmacologic treatments used to improve cognition: • Environmental manipulation that decreases stimulation • Aromatherapy, Massage, Music therapy, Exercise
  • 34. Drug Alert • Cholinesterase inhibitors initially aimed at improving memory and cognition seem to have an important impact on the behavioral changes that occur in patients with cognitive impairment • improves the apathy, disinhibition, pacing, and hallucinations commonly noted in dementia • Be alert for drug interactions with NSAIDs, succinylcholine-type muscle relaxants, cholinergic and anticholinergic agents, drugs that slow the heart, and other drugs
  • 35. Nursing assessment • Perform cognitive assessment • Orientation, insight, abstract thinking, concentration, memory, verbal ability • Assess for changes in behavior and ability to perform adls • Evaluate nutrition and hydration • Check weight, skin turgor, meal habits • Assess motor ability, strength, muscle tone, flexibility
  • 36. Nursing diagnoses • Self-care deficit • Constipation • Disabled family coping • Disturbed thought • Imbalanced nutrition: Less than body requirements Impaired verbal communication
  • 37. • Ineffective coping • Interrupted family processes • Risk for infection • Risk for injury
  • 38. Interventions • Establish an effective communication system with the patient and his family to help them adjust to the patient's altered cognitive abilities • Provide emotional support to the patient and his family • Encourage them to talk about their concerns • Listen carefully to them
  • 39. • Use a soft tone and a slow, calm manner when speaking to him Because the patient may misperceive his environment • Allow the patient sufficient time to answer your questions his thought processes are slow, impairing his ability to communicate verbally
  • 40. Intervention • Administer ordered medications to the patient and note their effects • If the patient has trouble swallowing, check with a pharmacist to see if tablets can be crushed or capsules can be opened and mixed with a semi- soft food • Protect the patient from injury • Provide a safe, structured environment • Provide rest periods between activities because these patients tire easily
  • 41. • Encourage the patient to exercise to help maintain mobility • Encourage patient independence allow ample time for the patient to perform tasks • Encourage sufficient fluid intake and adequate nutrition Provide assistance with menu selection allow the patient to feed himself as much as he can • Provide a well-balanced diet with adequate fiber • Avoid stimulants, such as coffee, tea, cola, and chocolate
  • 42. • Give the patient semisolid foods if he has dysphagia • Insert and care for a nasogastric tube or a gastrostomy tube for feeding as ordered • Because the patient may be disoriented or neuromuscular functioning may be impaired, take the patient to the bathroom at least every 2 hours • Assist the patient with hygiene and dressing as necessary • Many patients with Alzheimer's disease are incapable of performing these tasks
  • 43. Complication • Aspiration • Pneumonia and other infections • Falls • Fractures • Bedsores • Malnutrition or dehydration
  • 44. Prevention It is not a preventable condition. Lifestyle risk factors for Alzheimer's can be modified. Changes in diet, exercise and habits — steps to reduce the risk of cardiovascular disease — may also lower your risk of developing Alzheimer's disease
  • 45. Heart-healthy lifestyle choices that may reduce the risk of Alzheimer's include the following: • Exercise regularly • Eat a diet of fresh produce, healthy oils and foods low in saturated fat • Follow treatment guidelines to manage high blood pressure, diabetes and high cholesterol • Quit smoking